🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Treatment Gaining Traction Online

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged fat-burning properties. Followers are encouraged to message these accounts privately for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Additionally, a flourishing trade exists on messaging services, where communities with numerous of members share comparison photos, administration instructions and claims of next-day UK delivery. Vendors market the drug there before redirecting buyers to WhatsApp for purchases.

Understanding The Experimental Drug

Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Experts Voice Worries

However, physicians and chemists have cautions that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to users injecting substances of uncertain source.

Some professionals stated the demand for retatrutide could be connected to the increasing cost of licensed slimming treatments such as Mounjaro.

Regulatory Status and Implementation

Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be marketed or supplied for human use under the British medical regulations.

Several content creators try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach pharmaceutical, advertising, and customer regulations, risking fines, prosecution or prison.

Service Response and Content Removal

According to the social media company, the platform has removed problematic content and banned related hashtags and query recommendations. The organization said it was dedicated to keeping the service secure and investing in strengthening enforcement strategies.

Digital Trading Activities

Research also discovered groups with up to 9,000 members selling retatrutide using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of members, populated with photos of slimming results, positive reviews and detailed instructions for preparing or administering at home.

After minutes of entering one community, a seller posted WhatsApp details, where most purchases take place. The vendor sent an instruction manual and promised shipping within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None asked about body mass, health issues or previous experience.

Product Details and Costs

Inside these groups, posts display dark colored packages with postal service stickers, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at residence with purified liquid, or pre-filled pens typically priced at 160 pounds for 20mg. When asked how long a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Service Oversight and Safety Measures

A representative for the messaging service stated it actively moderated dangerous material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Expert Cautions

“People are injecting substances they cannot confirm. Even if the science behind retatrutide is sound, these online versions may not contain what they claim,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, patients are using social media. But counterfeit treatments are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were made in was clean,” she said.

Her staff has already encountered individuals injured by self-injection from unconfirmed sources. “We understand the frustration, but purchasing from messaging apps or communication platforms is taking chances with your health,” stated the doctor. “These substances could be impure or improperly measured.”

Producer Statement

A spokesperson from Eli Lilly said the substance was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly experimental product not yet approved … may subject patients to potentially serious health risks”.